Sanofi – Product Pipeline Review

Global Markets Direct’s, ‘Sanofi – Product Pipeline Review – 2016’, provides an overview of the Sanofi’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sanofi, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sanofi

The report provides overview of Sanofi including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sanofi’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sanofi’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sanofi’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sanofi

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sanofi’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sanofi Snapshot 6

Sanofi Overview 6

Key Information 6

Key Facts 6

Sanofi - Research and Development Overview 7

Key Therapeutic Areas 7

Sanofi - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Pipeline Products - Out-Licensed Products 19

Sanofi - Pipeline Products Glance 21

Sanofi - Late Stage Pipeline Products 21

Sanofi - Clinical Stage Pipeline Products 24

Sanofi - Early Stage Pipeline Products 26

Sanofi - Drug Profiles 28

(insulin glargine + lixisenatide) 28

lixisenatide 31

mipomersen sodium 35

semuloparin sodium 37

(fexofenadine hydrochloride + phenylephrine hydrochloride) 38

avanafil 39

cabazitaxel 40

insulin lispro 42

ziv-aflibercept (recombinant) 43

fexinidazole 47

(capecitabine + cyclophosphamide) 49

alemtuzumab 50

artefenomel + ferroquine 53

ataciguat 55

efpeglenatide 56

isatuximab 58

plerixafor 60

SAR-156597 63

sotagliflozin 64

pilaralisib 66

SAR-408701 69

SAR-421869 70

SAR-422459 72

voxtalisib 74

Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease 76

SAR-113244 77

SAR-228810 78

SAR-366234 79

SAR-407899 80

SAR-425899 81

SAR-428926 82

SAR-438335 83

SAR-438544 84

SAR-440067 85

SAR-566658 86

ACP-003 88

DCM-1 89

efpeglenatide + HM-12470 90

food allergy vaccine 91

Peptides for Tuberculosis 92

Recombinant Proteins for Pseudomonas aeruginosa Infection 93

SAR-088 95

SAR-110068 96

SAR-131675 97

SAR-156497 98

SAR-184841 99

SAR-216471 100

SAR-224 101

SAR-244181 102

SAR-296968 103

SAR-396049 104

SAR-7334 105

Small Molecule 4 for Tuberculosis 106

Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis 107

Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds 108

Monoclonal Antibodies for Infectious Disease 109

Monoclonal Antibodies for Neurodegenerative Diseases 110

Peptide for HIV and HSV Infections 111

SAR-405 112

Small Molecule 2 for Tuberculosis 113

Small Molecule 3 for Tuberculosis 114

Small Molecule for Calcific Aortic Valve Stenosis 115

Small Molecule for Duchenne Muscular Dystrophy 116

Small Molecules for Malaria 117

Small Molecules to Inhibit Protein Kinase for Undisclosed Indication 118

Vaccine for Celiac Disease 119

Vaccine for Food Allegy 2 120

Zika virus vaccine 121

Sanofi - Pipeline Analysis 122

Sanofi - Pipeline Products by Target 122

Sanofi - Pipeline Products by Route of Administration 126

Sanofi - Pipeline Products by Molecule Type 127

Sanofi - Pipeline Products by Mechanism of Action 128

Sanofi - Recent Pipeline Updates 131

Sanofi - Dormant Projects 161

Sanofi - Discontinued Pipeline Products 165

Discontinued Pipeline Product Profiles 167

Sanofi - Company Statement 178

Sanofi - Locations And Subsidiaries 179

Head Office 179

Other Locations & Subsidiaries 179

Sanofi - Key Manufacturing Facilities 194

Appendix 195

Methodology 195

Coverage 195

Secondary Research 195

Primary Research 195

Expert Panel Validation 195

Contact Us 195

Disclaimer 196

List of Tables

List of Tables

Sanofi, Key Information 13

Sanofi, Key Facts 13

Sanofi – Pipeline by Indication, 2016 15

Sanofi – Pipeline by Stage of Development, 2016 20

Sanofi – Monotherapy Products in Pipeline, 2016 21

Sanofi – Combination Treatment Modalities in Pipeline, 2016 22

Sanofi – Partnered Products in Pipeline, 2016 23

Sanofi – Partnered Products/ Combination Treatment Modalities, 2016 24

Sanofi – Out-Licensed Products in Pipeline, 2016 26

Sanofi – Out-Licensed Products/ Combination Treatment Modalities, 2016 27

Sanofi – Pre-Registration, 2016 28

Sanofi – Filing rejected/Withdrawn, 2016 29

Sanofi – Phase III, 2016 30

Sanofi – Phase II, 2016 31

Sanofi – Phase I, 2016 32

Sanofi – Preclinical, 2016 33

Sanofi – Discovery, 2016 34

Sanofi – Pipeline by Target, 2016 129

Sanofi – Pipeline by Route of Administration, 2016 133

Sanofi – Pipeline by Molecule Type, 2016 134

Sanofi – Pipeline Products by Mechanism of Action, 2016 135

Sanofi – Recent Pipeline Updates, 2016 138

Sanofi – Dormant Developmental Projects,2016 168

Sanofi – Discontinued Pipeline Products, 2016 172

Sanofi, Subsidiaries 186

Sanofi, Key Manufacturing Facilities 201

List of Figures

List of Figures

Sanofi – Pipeline by Top 10 Indication, 2016 15

Sanofi – Pipeline by Stage of Development, 2016 20

Sanofi – Monotherapy Products in Pipeline, 2016 21

Sanofi – Combination Treatment Modalities in Pipeline, 2016 22

Sanofi – Partnered Products in Pipeline, 2016 23

Sanofi – Out-Licensed Products in Pipeline, 2016 26

Sanofi – Pipeline by Top 10 Target, 2016 129

Sanofi – Pipeline by Route of Administration, 2016 133

Sanofi – Pipeline by Top 10 Molecule Type, 2016 134

Sanofi – Pipeline Products by Top 10 Mechanism of Action, 2016 135

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports